This is a routine corporate presentation update with no new material financial data. Key catalyst to watch is the initiation of the RECLAIM-LN Phase 2 trial in 2H 2026 and FT839 IND filing — both binary clinical events. Monitor for patient enrollment updates and potential partnership announcements given the cash runway guidance into 2028.
Price Chart
Executive Summary
Fate Therapeutics filed an 8-K on June 4, 2026, to update its corporate presentation for the EULAR 2026 Congress, highlighting Phase 1 data for FT819 in autoimmune diseases and the upcoming Phase 2 RECLAIM-LN registrational trial in lupus nephritis. The filing also included Q1 2026 financials showing $174.8M cash runway into 2028 and a 20% YoY OpEx reduction, but the primary content is a routine corporate update without new material financial disclosures.
Key Facts
- Corporate presentation updated for EULAR 2026 Congress on June 4, 2026.
- FT819-102 Phase 1 data: 26 patients dosed (22 SLE, 4 SSc, 3 IIM, 1 AAV); 21 activated clinical sites; 8 patients treated in outpatient settings.
- FT819-102 demonstrated no DLT, no Grade >2 CRS, ICANS, GvHD or deaths in 16 SLE Regimen A patients.
- RECLAIM-LN Phase 2 potentially registrational trial for lupus nephritis planned to begin patient dosing in 2H 2026 with 53-patient enrollment targeting BLA submission in 2028.
- Q1 2026 cash and short-term investments of $174.8M, with cash runway into 2028.
- Total OpEx reduction of 20% YoY in Q1 2026, with R&D down 15% and G&A down 30%.
- Weighted-average shares outstanding of 120.0M.
- FT839 IND filing planned 2H 2026; FT839 Phase 1 pan-autoimmune trial initiation 2H 2026.
Financial Impact
Cash runway into 2028 with $174.8M cash and investments; no revenue or EPS reported in filing.
Risk Factors
- Clinical trial execution risk for RECLAIM-LN Phase 2 enrollment timelines and outcomes.
- Regulatory risk: FT819's registrational path depends on alignment with FDA, which may shift timelines.
- Cash runway into 2028 provides buffer but ongoing R&D spend without revenue creates dilution risk.
- Competition in off-the-shelf CAR T-cell therapy space for autoimmune indications.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-257558 |
| Document: d83385d8k.htm | 0001193125-26-257558 |
| Document: 0001193125-26-257558-index-headers.html | 0001193125-26-257558 |
| Document: 0001193125-26-257558-index.html | 0001193125-26-257558 |
| Document: 0001193125-26-257558.txt | 0001193125-26-257558 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | Press Release | $2.57 $2.34 | ▼ −8.95% | ▼ −6.96% | $2.32 (−9.73%) |
Aug 13, 2026 7w ago | 8-K | $2.52 $2.31 | ▼ −8.33% | ▼ −6.59% | $2.32 (−7.94%) |
Aug 5, 2026 8w ago | Insider Cluster | $2.49 $2.42 | ▲ +2.81% | ▲ +3.41% | $2.32 (+6.83%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.97 $3.11 | ▼ −57.87% | ▼ −55.98% | $2.32 (−17.77%) |
Jun 4, 2026 17w ago | 8-K | $1.98 $2.99 | ▲ +51.01% | ▲ +49.15% | $2.32 (+17.17%) |
Jun 1, 2026 17w ago | Press Release | $2.74 $2.70 | ▼ −1.46% | ▼ −0.16% | $2.32 (−15.33%) |
May 13, 2026 20w ago | 8-K | $2.14 $1.97 | ▼ −7.94% | ▼ −7.33% | $2.32 (+8.41%) |
May 11, 2026 20w ago | Press Release | $2.18 $1.90 | ▼ −12.84% | ▼ −12.54% | $2.32 (+6.42%) |
Apr 24, 2026 23w ago | DEFA14A | $1.31 $2.15 | ▲ +64.12% | ▲ +59.17% | $2.32 (+77.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access